×

Warning

Joomla\CMS\Filesystem\Folder::create: Could not create folder.Path: /home/punr6yjxnk3r

Key folder in safepath unaccessible

Dostinex 2 tab / 0.5 mg

Print
dostineks-2-tab-po-05-mg.jpgdostineks-2-tab-po-05-mg.jpg
Base price $26.45
Description Pharmacological action

dopamine receptor Agonist. cabergoline - derived dopaminergic Ergoline, characterized by a pronounced and long prolactinemia action. The mechanism of action is direct stimulation of dopamine D2-receptors lactotropic cells of the pituitary gland. In doses than those to reduce the level of prolactin in plasma, exerts a Central dopaminergic effect due to stimulation of dopamine D2-receptors.

the Decrease in the concentration of prolactin in plasma observed after 3 h after drug administration and lasts for 7-28 days in healthy volunteers and patients with hyperprolactinemia, and up to 14-21 days in women in the postpartum period. Prolactinaemia effect is dose-dependent in relation to the severity and duration of the action.

cabergoline has a strictly selective effect, has no effect on basal secretion of other pituitary hormones and cortisol.

The pharmacological effects of cabergoline not related to therapeutic effect, applies only decreased blood pressure. In case of single use of the drug the maximum hypotensive effect observed during the first 6 h and is dose-dependent.

Dosage

is taken orally, during meals.

the Prevention of lactation: 1 mg (2 tab.) once on the first day after birth.

the Suppression of established lactation: 250 mcg (1/2 tab.) 2 times/day every 12 hours for 2 days (total dose is 1 mg). To reduce the risk of orthostatic hypotension at nursing mothers a single dose of dostinex should not exceed 250 mcg.

the Treatment of disorders related to hyperprolactinaemia: the recommended initial dose is 500 µg / week 1 (1 tab.) or 2 doses (1/2 tab., for example, Monday and Thursday). Increase weekly dose should be gradual - 500 micrograms at intervals of 1 month until the optimal therapeutic effect. Therapeutic dose is usually 1 mg per week but may range from 250 mg to 2 mg per week. The maximum dose for patients with hyperprolactinemia is 4.5 mg per week.

depending on the tolerability of a weekly dose can be taken once or divided into 2 or more receptions in a week. Splitting the weekly dose into multiple methods is recommended when administering the drug in a dose of 1 mg per week.

Side effects

In clinical studies with the drug Dostinex for prevention of physiological lactation (1 mg dose) and to suppress lactation (250 mg every 12 h for 2 days) adverse reactions were noted in approximately 14% of women. In applying the drug Dostinex for 6 months at a dose of 1-2 mg per week, divided into 2 doses, for the treatment of disorders associated with hyperprolactinemia, the frequency of adverse reactions was 68%. Adverse reactions occurred mainly during the first 2 weeks of therapy and in most cases disappear with continued therapy or a few days after discontinuation of the drug Dostinex. Adverse reactions were usually transient, severity weakly or moderately expressed and wore a dose-dependent character. At least once during therapy of severe side effects were observed in 14% of patients; adverse reactions, treatment was discontinued in approximately 3% of patients.

the Most frequent adverse reactions are presented below.

From the side of cardiovascular system: palpitations; rare - ortostatical gipotenzia (with prolonged use of the drug has a hypotensive effect); asymptomatic decrease in blood pressure during the first 3-4 days after birth (systolic - more than 20 mm Hg.St., diastolic more than 10 mm Hg.St.).

the part of the nervous system: dizziness/vertigo, headache, fatigue, drowsiness, depression, asthenia, paresthesia, syncope, nervousness, anxiety, insomnia, poor concentration.

Reviews

There are yet no reviews for this product.

Please publish modules in offcanvas position.